Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease

Biological intervention for Crohn's Disease (CDs) patients, mainly using anti-TNF antibodies, is often an efficient therapeutic solution. Nonetheless, data defining the administration timing to maximize the chances of clinical remission are lacking. The objective of this “real-life” retrospecti...

Full description

Bibliographic Details
Main Authors: Mauro Mastronardi, Margherita Curlo, Elisabetta Cavalcanti, Osvaldo Burattini, Renato Cuppone, Romina Tauro, Stefania De Santis, Grazia Serino, Pasqua Letizia Pesole, Elisa Stasi, Maria Lucia Caruso, Rossella Donghia, Vito Guerra, Pietro Giorgio, Marcello Chieppa
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Medicine
Subjects:
Crohn's disease
biological agents anti-TNF
Adalimumab
clinical outcome
clinical remission
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2019.00234/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2019.00234/full

Similar Items